Centerline Biomedical receives FDA 510(k) clearance for Intra-Operative Positioning System
Endroit courant :
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Operating Room Homepage

AJR publishes gender affirmation surgery primer for radiologists

FDA expands indication for several transcatheter heart valves

Edwards SAPIEN 3 TAVR receives FDA approval for low-risk patients

Unity Hospital first in New York State to offer radiation-free neurosurgery platform

Synaptive Medical launches surgical planning tool Modus Plan with added automated tractography segmentation capability

Surgical planning for head and neck cancer benefits from FDG-PET/CT

Reconstructing histological slices into 3D images

Study identifies human performance deficiencies associated with adverse surgical events

axial3D has announced the closing of a USD $3 million funding round

Most deaths related to noncardiac surgery occur after surgery and after discharge from hospital

Centerline Biomedical receives FDA 510(k) clearance for Intra-Operative Positioning System

Press releases may be edited for formatting or style
CLEVELAND, July 10, 2019 /PRNewswire/ -- Centerline Biomedical, Inc. (Centerline) has announced that the company has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its flagship product, the Intra-Operative Positioning System, IOPS.

A non-radiation-based surgical navigation system for minimally invasive surgery, IOPS leverages anatomical mapping algorithms and electromagnetic tracking technology to provide three-dimensional color visualization and guidance in real time during endovascular procedures. The system, developed at Cleveland Clinic's Heart and Vascular Institute, addresses the need for a path away from X-ray fluoroscopy which is currently the standard of care, despite severe visualization challenges.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



"To date, Cleveland Clinic has partnered with some 87 companies; among these, Centerline has been particularly rewarding and we are very excited about them having received 510(k) clearance. Most certainly as partners, shareholders, and prospective customers, we at Cleveland Clinic look forward to continuing support of the exciting research and commercialization efforts of this rapidly growing company," stated Jim Zalar, General Manager of Business Solutions at Cleveland Clinic Innovations and Cleveland Clinic's appointee to the company's Board of Directors.

Once in the market, Centerline hopes to show significant value to the technology by reducing procedure cost while improving radiation safety and patient outcomes. "Having worked closely with Centerline for almost five years, I am very pleased to see that IOPS will soon be commercially available," remarked Dr. Matthew Eagleton, Chief of Vascular Surgery at Massachusetts General Hospital and Chair of the company's Scientific Advisory Board. "We hope to use this game-changing technology to revolutionize our approach to vascular procedures and imaging."

This milestone, achieved working with regulatory partner JALEX Medical, will allow marketing and commercial use of IOPS for endovascular interventions in the descending aorta, though the underlying platform will be applicable to many other minimally invasive procedures in the future. Such future indications may include structural heart interventions, an application the company is currently exploring with funding from an NIH small business grant. The company's R&D efforts will continue in parallel with Centerline's upcoming market launch.


SOURCE Centerline Biomedical

Operating Room Homepage


You Must Be Logged In To Post A Comment